179 related articles for article (PubMed ID: 27663383)
1. A Comprehensive Evaluation of Nanoparticle Tracking Analysis (NanoSight) for Characterization of Proteinaceous Submicron Particles.
Tian X; Nejadnik MR; Baunsgaard D; Henriksen A; Rischel C; Jiskoot W
J Pharm Sci; 2016 Nov; 105(11):3366-3375. PubMed ID: 27663383
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Nanoparticle Tracking Analysis for Quantification and Sizing of Submicron Particles of Therapeutic Proteins.
Zhou C; Krueger AB; Barnard JG; Qi W; Carpenter JF
J Pharm Sci; 2015 Aug; 104(8):2441-50. PubMed ID: 26017684
[TBL] [Abstract][Full Text] [Related]
3. Interference from Proteins and Surfactants on Particle Size Distributions Measured by Nanoparticle Tracking Analysis (NTA).
Bai K; Barnett GV; Kar SR; Das TK
Pharm Res; 2017 Apr; 34(4):800-808. PubMed ID: 28155075
[TBL] [Abstract][Full Text] [Related]
4. Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates.
Filipe V; Hawe A; Jiskoot W
Pharm Res; 2010 May; 27(5):796-810. PubMed ID: 20204471
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle tracking analysis of particle size and concentration detection in suspensions of polymer and protein samples: Influence of experimental and data evaluation parameters.
Gross J; Sayle S; Karow AR; Bakowsky U; Garidel P
Eur J Pharm Biopharm; 2016 Jul; 104():30-41. PubMed ID: 27108267
[TBL] [Abstract][Full Text] [Related]
6. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags.
Kumru OS; Liu J; Ji JA; Cheng W; Wang YJ; Wang T; Joshi SB; Middaugh CR; Volkin DB
J Pharm Sci; 2012 Oct; 101(10):3636-50. PubMed ID: 22733600
[TBL] [Abstract][Full Text] [Related]
7. Practical Considerations for Detection and Characterization of Sub-Micron Particles in Protein Solutions by Nanoparticle Tracking Analysis.
Gruia F; Parupudi A; Polozova A
PDA J Pharm Sci Technol; 2015; 69(3):427-39. PubMed ID: 26048748
[TBL] [Abstract][Full Text] [Related]
8. Characterization of submicron (0.1-1 μm) particles in therapeutic proteins by nanoparticle tracking analysis.
Vasudev R; Mathew S; Afonina N
J Pharm Sci; 2015 May; 104(5):1622-31. PubMed ID: 25737284
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle Tracking Analysis to Examine the Temperature-Induced Aggregation of Proteins.
Sladek S; McComiskey K; Healy AM; Tajber L
Methods Mol Biol; 2019; 2039():131-139. PubMed ID: 31342424
[TBL] [Abstract][Full Text] [Related]
10. Factors Governing the Accuracy of Subvisible Particle Counting Methods.
Ríos Quiroz A; Finkler C; Huwyler J; Mahler HC; Schmidt R; Koulov AV
J Pharm Sci; 2016 Jul; 105(7):2042-52. PubMed ID: 27287519
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress.
Telikepalli S; Kumru OS; Kim JH; Joshi SB; O'Berry KB; Blake-Haskins AW; Perkins MD; Middaugh CR; Volkin DB
J Pharm Sci; 2015 Feb; 104(2):495-507. PubMed ID: 25522000
[TBL] [Abstract][Full Text] [Related]
12. Detection and Sizing of Submicron Particles in Biologics With Interferometric Scattering Microscopy.
Wong NA; Uchida NV; Dissanayake TU; Patel M; Iqbal M; Woehl TJ
J Pharm Sci; 2020 Jan; 109(1):881-890. PubMed ID: 31160046
[TBL] [Abstract][Full Text] [Related]
13. A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein Products.
Hubert M; Yang DT; Kwok SC; Rios A; Das TK; Patel A; Wuchner K; Antochshuk V; Junge F; Bou-Assaf GM; Cao S; Saggu M; Montrond L; Afonina N; Kolhe P; Loladze V; Narhi L
J Pharm Sci; 2020 Jan; 109(1):830-844. PubMed ID: 31647951
[TBL] [Abstract][Full Text] [Related]
14. Label-free flow cytometry analysis of subvisible aggregates in liquid IgG1 antibody formulations.
Nishi H; Mathäs R; Fürst R; Winter G
J Pharm Sci; 2014 Jan; 103(1):90-9. PubMed ID: 24218205
[TBL] [Abstract][Full Text] [Related]
15. Fluorescence single particle tracking for the characterization of submicron protein aggregates in biological fluids and complex formulations.
Filipe V; Poole R; Kutscher M; Forier K; Braeckmans K; Jiskoot W
Pharm Res; 2011 May; 28(5):1112-20. PubMed ID: 21298328
[TBL] [Abstract][Full Text] [Related]
16. Effects of submicron particles on formation of micron-sized particles during long-term storage of an interferon-β-1a solution.
Bai S; Murugesan Y; Vlasic M; Karpes LB; Brader ML
J Pharm Sci; 2013 Feb; 102(2):347-51. PubMed ID: 23233283
[TBL] [Abstract][Full Text] [Related]
17. Using Image Attributes to Assure Accurate Particle Size and Count Using Nanoparticle Tracking Analysis.
Defante AP; Vreeland WN; Benkstein KD; Ripple DC
J Pharm Sci; 2018 May; 107(5):1383-1391. PubMed ID: 29277640
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive understanding of nano-sized particle separation processes using nanoparticle tracking analysis.
Lawler DF; Youn S; Zhu T; Kim I; Lau BL
Water Sci Technol; 2015; 72(12):2318-24. PubMed ID: 26676021
[TBL] [Abstract][Full Text] [Related]
19. Comparison of particle size methodology and assessment of nanoparticle tracking analysis (NTA) as a tool for live monitoring of crystallisation pathways.
McComiskey KPM; Tajber L
Eur J Pharm Biopharm; 2018 Sep; 130():314-326. PubMed ID: 30012404
[TBL] [Abstract][Full Text] [Related]
20. Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting.
Telikepalli S; Shinogle HE; Thapa PS; Kim JH; Deshpande M; Jawa V; Middaugh CR; Narhi LO; Joubert MK; Volkin DB
J Pharm Sci; 2015 May; 104(5):1575-91. PubMed ID: 25753756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
